WEFM, A., M, B., R, D., LM, K., GFA, C., RFA, d. C., . . . C, P. (2019). CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy. BMC cancer, 19(1), 1173. https://doi.org/10.1186/s12885-019-6353-2
Chicago Style (17th ed.) CitationWEFM, Alves, et al. "CAIX Is a Predictor of Pathological Complete Response and Is Associated with Higher Survival in Locally Advanced Breast Cancer Submitted to Neoadjuvant Chemotherapy." BMC Cancer 19, no. 1 (2019): 1173. https://doi.org/10.1186/s12885-019-6353-2.
MLA (9th ed.) CitationWEFM, Alves, et al. "CAIX Is a Predictor of Pathological Complete Response and Is Associated with Higher Survival in Locally Advanced Breast Cancer Submitted to Neoadjuvant Chemotherapy." BMC Cancer, vol. 19, no. 1, 2019, p. 1173, https://doi.org/10.1186/s12885-019-6353-2.
